Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Australia"

181 News Found

Merck launches international platform to discuss ‘Next-Gen Labs’
News | July 06, 2022

Merck launches international platform to discuss ‘Next-Gen Labs’

Merck is organizing one of the biggest South APAC Virtual Conclave on ‘Next-Gen Labs’ on 20th July.


Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
News | July 01, 2022

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia


Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus
Diagnostic Center | June 10, 2022

Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus

Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.


Merck’s pembrolizumab demonstrates improvement in distant metastasis
News | June 06, 2022

Merck’s pembrolizumab demonstrates improvement in distant metastasis

Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).


AstraZeneca’s Pascal Soriot awarded British knighthood for services to UK
People | June 04, 2022

AstraZeneca’s Pascal Soriot awarded British knighthood for services to UK

AstraZeneca also played a critical role in the global response to COVID-19.


Novavax initiates phase 3 trial of its COVID-19 omicron booster
Biotech | June 01, 2022

Novavax initiates phase 3 trial of its COVID-19 omicron booster

Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19


New data demonstrate clinical benefit of Roche’s glofitamab
Biotech | May 27, 2022

New data demonstrate clinical benefit of Roche’s glofitamab

Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma


Novavax files for expanded conditional marketing authorisation for Nuvaxovid as a booster in Europe
News | May 21, 2022

Novavax files for expanded conditional marketing authorisation for Nuvaxovid as a booster in Europe

The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022


AbbVie submits NDA for treatment of advanced Parkinson’s disease
Biotech | May 21, 2022

AbbVie submits NDA for treatment of advanced Parkinson’s disease

If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs


City of Hope and Imugene dose patient in Phase 1 trial to test cancer-killing oncolytic virus
Biotech | May 18, 2022

City of Hope and Imugene dose patient in Phase 1 trial to test cancer-killing oncolytic virus

City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours